Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

DSM Readies Aussie Biologics Facility

by Michael McCoy
April 29, 2013 | A version of this story appeared in Volume 91, Issue 17

[+]Enlarge
Credit: DSM
An artist’s rendition of DSM’s new facility in Australia.
An artist’s conception of DSM biologics facility to open in June 2013 in Brisbane, Australia.
Credit: DSM
An artist’s rendition of DSM’s new facility in Australia.

DSM plans a June start-up for its cGMP biologic drugs facility in Brisbane, Australia. Built with cooperation from local and national government agencies, the 500-kg-per-year facility will be Australia’s first custom mammalian-cell-based biopharmaceutical plant. Separately, DSM has signed an agreement to manufacture a therapeutic antibody for Cambridge, Mass.-based DecImmune Therapeutics. Initial development will take place in DSM’s plant in Groningen, the Netherlands; manufacturing of clinical trial material would occur at the new Australian site.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.